[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626640":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":45,"responsibleParty":66,"collaborators":68,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":26,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":97,"whyStopped":26,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Australian and New Zealand Intensive Care Research Centre","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention Arm - Synthamin-17 electrolyte-free solution","ACTIVE_COMPARATOR","The study drug within the intervention arm will be continually infused for up to 48 hours whilst the patient is on ECMO. The infusion rate will be set to 2g\u002Fkg\u002Fideal body weight\u002Fday (to a maximum of 100g). Patients enrolled into the control arm will be continually infused with a placebo for up to 48 hours whilst on ECMO.",[13],"Dietary Supplement: Synthamin-17 (10% amino acid solution)",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Arm - Hartmann's balanced crystalloid solution","PLACEBO_COMPARATOR","Participants allocated to the control group will receive placebo comprised of Hartmann's balanced crystalloid solution (compound sodium lactate) to a maximum of 500mls and 48-hours.",[19],"Other: Placebo (Hartmann's balanced crystalloid solution)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","Synthamin-17 (10% amino acid solution)","First time comparing amino acid to placebo for prevention of acute kidney injury in patients receiving extracorporeal membrane oxygenation",[9],null,{"type":6,"name":28,"description":17,"armGroupLabels":29,"otherNames":26},"Placebo (Hartmann's balanced crystalloid solution)",[15],[31],{"name":32,"affiliation":33,"role":34},"Carol Hodgson, FAHMS","Monash University, School of Public Health and Preventative Medicine, ANZIC-RC","STUDY_CHAIR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Aidan Burrell, MBBS, FCICM, DDU, PhD","CONTACT","+61 422 848 716","aidanburrell@gmail.com",{"name":42,"role":38,"phone":43,"phoneExt":26,"email":44},"Stephanie M Hunter, BN, PhD","+61 422 033 612","Stephanie.Hunter@monash.edu",[46],{"facility":47,"status":26,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Alfred Hospital","Melbourne","Victoria","3004","Australia","AU",{"type":54,"coordinates":55},"Point",[56,57],144.96332,-37.814,{"lat":57,"lon":56},[60,64],{"name":61,"role":38,"phone":62,"phoneExt":26,"email":63},"Andrew Udy, BHB, MB ChB, PGCert (AME) PhD","+61 03 9076 8347","A.Udy@alfred.org.au",{"name":65,"role":38,"phone":62,"phoneExt":26,"email":26},"Emma-Leah Martin",{"type":67,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[69,71],{"name":70,"class":6},"Monash University",{"name":72,"class":6},"The Alfred","100626640","phase-2-the-aminoecmo-pilot-trial-100626640",false,"NCT07438262","The AminoECMO Pilot Trial","A Pilot, Three-centre, Placebo Controlled, Physiology and Feasibility Randomised Controlled Trial of Intravenous Amino Acid Therapy in ECMO Dependent Adults Admitted to the Intensive Care Unit","AminoECMO","Inclusion Criteria:\n\n* Aged ≥18 years\n* Enrolled in the EXCEL Registry\n\nExclusion Criteria:\n\n* Urea level ≥30 mmol\u002FL\n* Requirement for renal replacement therapy\n* Chronic hemodialysis or peritoneal dialysis\n* ECMO for ≥24 hours\n* Pre-admission CKD with an eGFR \\\u003C30 ml\u002Fmin\n* Previous enrolment in this study\n* Pregnant or Lactating\n* Known contraindication to AA infusion\n* ECMO expected to cease ≤24 hours\n* Expected to be transferred to another hospital ≤24 hours\n* Treating clinical team deems study is not in the patient's best interest","ALL","18 Years","65 Years",{"count":85,"type":86},40,"ESTIMATED","INTERVENTIONAL",[89],"PHASE2","Acute kidney injury (AKI) is a serious problem for patients in intensive care, especially those on life-support machines like ECMO (which helps the heart and lungs). More than half of these patients develop severe kidney problems that often require dialysis, and this greatly increases the risk of poor outcomes.\n\nDoctors try to prevent AKI by treating the underlying illness, avoiding kidney-harming drugs, and carefully managing fluids. But these methods are mostly supportive - they don't actively improve kidney function.\n\nStudies in surgical patients (especially heart and urology operations) show that giving amino acids before surgery can reduce the chance of developing AKI. A major clinical trial even found that this approach significantly lowered AKI rates in heart surgery patients.\n\nAmino acids (the building blocks of protein) seem to boost kidney performance. When given through a drip or feeding tube, they increase blood flow to the kidneys and may \"wake up\" unused kidney capacity - a concept called \"functional renal reserve.\" It's not yet clear whether amino acids help critically ill patients on ECMO. More research is needed to see if this promising strategy can improve kidney function and outcomes in the sickest patients.",[92],"Acute Kidney Injury",[94,95,96],"Acute kidney injury","Extracorporeal Membrane Oxygenation","Amino Acids","NOT_YET_RECRUITING","2026-02-22",{"date":100,"type":101},"2026-02-27","ACTUAL",{"date":103,"type":86},"2026-02-01",{"date":105,"type":86},"2027-11-30",{"name":5,"class":6},1]